Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of postoperative
adjuvant treatment of pembrolizumab in patients with thoracic esophageal squamous cell
carcinoma （ESCC） who have not received neoadjuvant therapy before undergoing R0 resection,
and have positive postoperative lymph nodes.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital